NVIDIA launches Jetson Thor robotics computers for physical AI systems
Richard M. Jelinek, a director at Evolent Health, Inc. (NYSE:EVH), recently acquired a significant amount of the company’s stock, showing confidence despite the stock’s 73% decline over the past year. According to InvestingPro data, the stock currently trades at $8.99, near its 52-week low of $8.35. On March 7, Jelinek purchased a total of 30,000 shares of Class A Common Stock through two separate transactions. The shares were acquired at prices ranging from $9.09 to $9.16 per share, resulting in a total transaction value of $273,750. This insider purchase aligns with broader management activity, as InvestingPro analysis shows management has been actively buying back shares. The company appears undervalued according to InvestingPro’s Fair Value analysis.
The purchases were made through the Richard M Jelinek Revocable Trust and the Richard M Jelinek GST. Following these transactions, Jelinek’s direct ownership includes 14,458 shares, which also accounts for restricted stock units previously reported in earlier filings.
These acquisitions reflect Jelinek’s continued investment in Evolent Health as the company continues to navigate the healthcare management services sector. With a market capitalization of $1.03 billion, Evolent Health shows potential despite current challenges. Discover more insights about EVH and track insider trading patterns with InvestingPro, which offers 8 additional exclusive tips about the company’s performance and outlook.
In other recent news, Evolent Health reported its fourth-quarter results, which did not meet analyst expectations, with adjusted earnings per share at -$0.02 compared to the anticipated $0.07. The company generated $646.5 million in revenue, falling short of the $652.2 million forecasted by analysts, although this represented a 16.3% increase year-over-year. For the full year 2024, Evolent Health’s revenue reached $2.55 billion, marking a 30.1% growth from 2023. However, its 2025 revenue guidance between $2.06 billion and $2.11 billion was notably below the $2.42 billion expected by analysts.
Piper Sandler adjusted its price target for Evolent Health to $16 from $17, maintaining an Overweight rating despite the company’s earnings falling at the lower end of its guidance. The firm highlighted Evolent Health’s strong bookings and full retention of top customers as positive indicators. Meanwhile, Citizens JMP raised its price target for Evolent Health to $13 from $12, reaffirming a Market Outperform rating. The analyst expressed confidence in the company’s management and its ability to navigate challenges in 2024.
Evolent Health’s recent earnings report and analyst assessments reflect a mixed outlook, with some optimism about the company’s strategic direction and customer retention. The company’s contract amendments and new revenue agreements are expected to improve financial performance in 2025. Investors continue to monitor these developments closely, considering the varied analyst perspectives on Evolent Health’s future potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.